Kraig Biocraft Laboratories Prepares for Silk Production Season

ANN ARBOR, Mich., – December 06, 2023 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, today announced that its senior management team is en route to Vietnam to prepare for the spring rearing season.  They will meet with the team from its wholly owned Vietnamese subsidiary, Prodigy Textiles, third-party contractors, and government officials, including provincial leadership.

This trip will lay the groundwork for the upcoming spring rearing season, strengthening its team, and preparing its facilities.  The Company is leveraging the winter offseason to align its staff and contractors to ensure ideal conditions for the launch of the 2024 season.  Senior management will also meet with hatcheries and spinners to look for opportunities to expand the Company’s integration into the supply chain and to vet additional production locations and partners, for 2024 and beyond.

Kraig Labs U.S. team just concluded a very productive month of onsite work with it senior sericulture consultant for India. Following up on that work, management plans to implement advanced rearing protocol across all of its operations domestically and overseas. The Company also plans to bring these consultants to Vietnam in the spring of 2024 to work directly with its production team as the Company builds out its capabilities.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (, a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

Kraig Biocraft Laboratories, Inc.

2723 South State Street Suite 150
Ann Arbor, Michigan 48104

Phone: (734) 619-8066

Corporate Website: